Skye Bioscience’s nimacimab blocks CB1, the same receptor targeted by an obesity drug candidate now in the hands of Novo Nordisk. But Skye contends its Phase 2-ready antibody drug has several advantages over the small molecule that joined Novo’s pipeline in a deal valued at $1 billion.
The Aerie Pharma acquisition brings Alcon two commercialized glaucoma products, as well as a pipeline of programs in various stages of development for other eye diseases. Alcon has been an active dealmaker, turning to M&A as a way to bolster its eye products portfolio and pipeline.
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
The company's technology for screening diabetic retinopathy was granted "Breakthrough Device" designation and is able to provide a clinical decision, instead of simply a recommendation to the physician.
Orange County, California-based Glaukos announced that the approval indicates use of the device, along with cataract surgery, makes it the first micro-invasive glaucoma surgery in Japan.
Applications and video games could be the next best way to assess eye health. That's the approach Vizzario it taking.
InnFocus has raised funds to further develop its InnFocus MicroShunt glaucoma drainage system to treat early, moderate, and late stage primary open angle glaucoma.
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.